Another interesting presentation by @Khanna_S showing efficacy of a microbiome-based treatment for recurrent C diff. A purified Firmicutes spore preparation was given orally and had low recurrence rate of C diff.▶️ 6.5% 1st recurrence▶️ 9.7% 2nd recurrent#Cdiff #ACG2022 pic.twitter.com/Ftb5dYKkcX— Mark B. Pochapin, MD (@MarkPochapin) October 26, 2022
OpenBiome, a pioneering stool and biobank, is announcing an expanded mission to accelerate global microbiome research—which is currently centered around high-income, industrialized countries—into a more inclusive science that transforms public health around the world.
RBX2660 Could Heal Recurrent C Diff Patients, Physically and Psychologically - Contagionlive.com
C diff patients live in fear of a recurrence, says gastroenterologist Paul Feuerstadt, MD. RBX2660 has entered the FDA pipeline and looks to end this vicious cycle.
Evaluating microbial determinants of donor efficacy to translate faecal microbiota transplantation from research to clinical practice | Gut
After becoming an established therapy for recurrent Clostridioides difficile infection (rCDI), faecal microbiota transplantation (FMT) has been investigated also in non-communicable disorders, including IBD, IBS, metabolic syndrome, neurological disease and others.1 While the transfer of a healthy biomass appears to be effective regardless of its composition in rCDI (which is an example of acute, elementary dysbiosis), increasing evidence suggests that the clinical success of FMT in chronic disorders is influenced by several factors, including donor microbiome composition2 or FMT working protocols,3 and that these effects may be mediated by the engraftment capacity of the donor microbiome into the recipient gut.4 Haifer et al 5 have published in the latest issue of Gut a subanalysis of a recent randomised trial (the LOTUS trial) of FMT for UC,6 where they had observed a significant variability of clinical efficacy between the two recruited donors (100% vs 36%). They have determined the differences in donor microbiome profiles by whole genome sequencing and untargeted metabolomics, validating results in another independent cohort, with a series of major findings.5 First, donors and patients with UC differed significantly in the composition and function of gut microbiota, in line with previous experiences. More strikingly, the stability in richness of donor species over time (assessed for up to 70 weeks), rather than richness itself, was associated with therapeutic efficacy. Along with this result, evenness of donor species was associated with higher donor engraftment as well as with clinical response, and the stability of less effective donor appeared to be …
Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light - PubMed
Immunotherapy is revolutionizing tumor treatment by activating the immune response to tumors. Among them, immunotherapy represented by immune checkpoint inhibitors is considered to be a milestone in tumor treatment. It has revolutionized the management of advanced malignant tumors by activating T ce …
Reduced alcohol preference and intake after fecal transplant in patients with alcohol use disorder is transmissible to germ-free mice
Nature Communications - Gut microbiota composition is altered in patients with alcohol use disorder, and fecal microbiota transplant reduced alcohol craving in patients with alcohol use disorder...
Fulminant: fluids, surgery consult, imaging, high dose vancomycin AND metronidazoleWith ileus, consider vancomycin enemaIf no response in 24-28 h, consider ✂️ New recommendation: can consider multiple (avg 3) #FMT +vanc for 1st episode pic.twitter.com/WxdSfljrJF— John Damianos, M.D. (@john_damianosMD) October 23, 2021
Sahil Khanna, MBBS, MS, FACG, AGAF (he/him) on Twitter
@tariqraseen, superstar GI fellow at @MayoClinicGIHep presenting seminal work on the effect of #FMT for #Cdiff on concurrent #UTIs at #ACG2022 @AmCollegeGastro pic.twitter.com/d55GPVdtft— Sahil Khanna, MBBS, MS, FACG, AGAF (he/him) (@Khanna_S) October 24, 2022
Sahil Khanna, MBBS, MS, FACG, AGAF (he/him) on Twitter
So proud to see the meta-analysis done on Efficacy of FMT for C.diff by @tariqraseen being cited at every talk on #Cdiff #ACG2022@DrPaulGastro @AmCollegeGastro pic.twitter.com/qPiq8RmjDF— Sahil Khanna, MBBS, MS, FACG, AGAF (he/him) (@Khanna_S) October 24, 2022
Fecal microbiota transplantation remains useful for #Cdiff, but “the next generation of treatments are microbiota-based live biotherapeutics,” @DrPaulGastro noted during #ACG2022 https://t.co/1ydga4h9ho #GITwitter #WeAreGI pic.twitter.com/438BlatEvE— Healio Gastroenterology (@HealioGastro) October 24, 2022
Fecal microbiota transplantation: targets the underlying pathophysiology of rCDI— dysbiosis NOT FDA approved (considered “experimental”) Many ways to deliver #FMT
Fecal microbiota transplantation: targets the underlying pathophysiology of rCDI— dysbiosis NOT FDA approved (considered “experimental”)Many ways to deliver #FMT pic.twitter.com/Sg5FwneJMQ— John Damianos, M.D. (@john_damianosMD) October 23, 2022
#FMT eliminated C. difficile AND restores the microbiota Efficacy: 67-82%
#FMT eliminated C. difficile AND restores the microbiota Efficacy: 67-82% pic.twitter.com/FMVbBJsQfw— John Damianos, M.D. (@john_damianosMD) October 23, 2022
#FMT beats antibiotics for rCDI ⭐️ We should be offering our patients with rCDI therapies that restore the microbiota
#FMT beats antibiotics for rCDI⭐️ We should be offering our patients with rCDI therapies that restore the microbiota pic.twitter.com/nshOYxIrsD— John Damianos, M.D. (@john_damianosMD) October 23, 2022
Why 🦠MICROBIOME is THE MOST important WORD in science in this YEAR? 🤦 👇 The pathomechanism of stomach ulceration was not so complicated cause the was only ONE bacteria 😉 but in @IBD 🤓👇 👇 #IBD #FMT #CD #UC #GUThealth #MICROBIOME @AGA_G
Why 🦠MICROBIOME is THE MOST important WORD in science in this YEAR? 🤦👇The pathomechanism of stomach ulceration was not so complicated cause the was only ONE bacteria 😉 but in @IBD 🤓👇👇#IBD #FMT #CD #UC#GUThealth#MICROBIOME@AGA_Gastro 👇👇https://t.co/0hIlpX76ur pic.twitter.com/teT4OoNMNk— Robert Dudkowiak MD, PhD (@drRobinDud) October 23, 2022
Malnutrition Results in Worse Outcomes for C Difficile Patients - MD Magazine
In data presented during ACG, investigators found patients with malnutrition and CDI had higher mortality and increased hospitals costs compared to those without malnutrition.
Some interesting work continuing on the possibility of #FMT for the treatment of #IBD with focus on #ulcerativecolitis supported by #diet interventions.Something many global experts are focused on but we're not quite there yet 🧵 (a few neat studies to read) https://t.co/7nAcHlBIMx— Dr. Heather Armstrong (@DrHArmstrong) October 22, 2022
Today @AmCollegeGastro #Autism: More than hope. Non-verbal 19 yr old says mama after fecal transplant using sister’s poo as a donor & shows improved microbiome. This case demonstrates that in some kids, Autism is a gut dysbiosis. Share and Support @Progenabiome 🙏 pic.twitter.com/L8ZAPEapXA— sabine hazan md (@SabinehazanMD) October 23, 2022
For 18 years, she needed steroids to control her colitis. Now, with poop therapy, she has got rid of them
Dr (Col) Avnish Seth, Head of Medical Gastroenterology, Hepatology and Manipal Organ Sharing & Transplant, at Manipal Hospital, Dwarka, performs Fecal Microbiota Transplant (FMT) on a 27-year-old patient. This is a process of transferring fecal bacteria and other microbes from a healthy individual into another individual through colonoscopy so that the imbalance between bad and good bacteria can be restored in the gut
A Health-Related Quality of Life questionnaire designed to gather data on an investigational #microbiota therapeutic demonstrated patients felt better about their conditions. #cdiff #IDWeek2022
A Health-Related Quality of Life questionnaire designed to gather data on an investigational #microbiota therapeutic demonstrated patients felt better about their conditions. #cdiff #IDWeek2022https://t.co/AtOMMFjJnJ— Contagion (@Contagion_Live) October 19, 2022
A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder - PubMed
This phase 1 trial shows that FMT is safe and associated with short-term reduction in alcohol craving and consumption with favorable microbial changes versus placebo in patients with alcohol-associated cirrhosis with alcohol misuse. There was also a reduction in AUD-related events over 6 months in p …
Webinar hosted by DWS: Faecal Microbiota Transplantation and the Clinical Potential of the Human Microbiome
Don Whitley Scientific is pleased to present ‘Faecal Microbiota Transplantation and the Clinical Potential of the Human Microbiome’, scheduled for 23rd November 2022 at 9:00-11:00 (BST). The webinar will feature three international speakers and is free to
Pharmaceutical Production Manager - Quadram Institute
We're looking for a Pharmaceutical Production Manager for our new Faecal Microbiota Transplant (FMT) Facility.BackgroundWe are seeking an experienced Pharmaceutical Production Manager with an inte
FMT in IBS: 'We've Been Targeting Wrong Part of the Intestine'
When administered to the small, rather than the more commonly used large, intestine, fecal microbiota transplantation results in sustained and better response rates in IBS, according to a new study.
Microbiota: can they prevent #TID?▶️ Freezedried capsules have been developed for #FMT treatment▶️Improving #microbiota diversity is a challenge-N. Hanssen#ISPAD #ISPAD2022 #dedoc°voices #NothingAboutUsWithoutUs #payitforward @dedocORG @ispad_org 4/n pic.twitter.com/xhloWaVbuT— Nat’s Pancreas 404 🐝 #COVIDisAirborne (@1derfultype) October 15, 2022
